|Year : 2020 | Volume
| Issue : 4 | Page : 547-549
Sneha Jatan Bothra1, Arpan Jain2
1 Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, Delhi, India
2 Department of Gastroenterology, Gobind Ballabh Pant Institute of Postgraduate Medical Education and Research, New Delhi, India
|Date of Submission||31-Jan-2020|
|Date of Decision||01-Jun-2020|
|Date of Acceptance||04-Jun-2020|
|Date of Web Publication||29-Aug-2020|
Dr. Sneha Jatan Bothra
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Bothra SJ, Jain A. Survival plots. Indian J Med Paediatr Oncol 2020;41:547-9
| Introduction|| |
Survival plot is usually a short note. It was asked in December 2019 DNB final theory examination. Let us look at this to understand survival plots which is one of the most common plots we see in oncology trials, and most drug approvals, are based on improvement in various survival times. There are various terms associated with survival analysis.
- Survival analysis: it is a different branch of statistics, that mainly deals with analyzing the outcome of patients till some event of interest occurs, or simply an analysis to estimate the survival of patients in a given set of data
- Survival time is the “statistics that measures time of follow-up from a predefined point of start (i.e., from the time of randomization or diagnosis) to the occurrence of a given event (relapse, progression, or death),”
- Survival plot/survival curve is a term that is “used to represent a group of plots that are constructed based on the time to event data.” It measures the fractions or percentage of patients living for a particular or specific amount of time after randomization, intervention, or treatment.
| Q1: How and Why Is Survival Analysis Different from Usual Statistics?|| |
Survival analysis was initially used in trials, where the event was “Death,” however, over time this survival analysis is being used for various indications inclusion, time to onset of disease, time to progression, time to discharge, etc.,
- The distribution of patients population is very rarely normal
- All members do not enter the study at the same time, and hence, usually have a different follow up time
- This dataset usually has censoring (in a few patients, the predefined event of interest may not have occurred till the end of the study) which is usually not the case with usual statistics. Hence, the usual statistical techniques cannot be applied here.
| Q2. What Are the Different Types of Survival Analysis and Plots? Advantage and Disadvantages of Various Types?|| |
Different types of survival curves
- Life table analysis
- Kaplan–Meier (K-M) survival curve.
Life table analysis
In this method, the total duration of follow-up is divided into intervals of fixed duration. For each of these intervals, calculations are made for those patients who reached the end point (or event). Thus, a proportion is calculated of the patients who had an event to those who were at risk at the beginning of the interval. For each succeeding interval, the same proportions are calculated and the cumulative survival is calculated.
In this paper, we will be getting into details of the K-M curve. In 1958, Edward L. Kaplan and Paul Meier published their work on how to understand and interpret incomplete observations. It was defined as “the probability of surviving in a given length of time while considering time in many small intervals.”
While analyzing the survival data, there are two functions, which are dependent on time (t):
- Survival function: “the probability of surviving (as predefined in the event of interest) to time (t)”
- Hazard function: it is defined as “the conditional probability of having death (as event of interest) at time t, having survived till that time.”
The main difference between the life table analysis and K-M survival analysis is that, K-M survival is applied when individual patient data are accessible, and instead of a fixed interval, the survival is analyses step wise with each event. The advantage is that K-M survival analysis provides more accurate survival estimates.
| Q3. What Are the Different Definitions in Relation to Survival Function?|| |
- Time to event: “it is the time (clinical course duration) to the predefined event of interest and is variable for each patient, which begins and ends anywhere along timeline of entire study”. It “Begins” when the patient is either enrolled or randomized or when the treatment begins. It “Ends” when end point or predefined event has occurred, or the patient is censored from the study
- Event: it could be death, or it may even sometimes be time to nonfatal events like recurrence, progression or may even be some favorable outcome like time to discharge from hospital
- Serial Time [Figure 1]: “The duration of the event of interest is called the serial time”
- Censoring: “it indicates that, time for which a particular patient survives, cannot be measured accurately.” It occurs if:
|Figure 1: Illustrates subjects entering a trial and ending at different times. The solid circle represents an event occurrence and the open circles represent censoring|
Click here to view
- Something negative happens, i.e., lost to follow-up, drop out, or if the data which is required are unavailable
- Something positive happens, i.e., the study ends before the patient has had the predefined event.
- Interval: “serial time duration of known survival is terminated by predefined event of interest is known as “interval” in K-M analysis.” Only event occurrences define known survival time intervals
- Survival curve: “defined as the graph of survival S(t) against time t”
- Time to progression: “time from randomization to disease progression” (death is censored at the time of death or at an earlier visit)
- Progression free survival: It is defined as the time from randomization to disease progression or death”
- Time to treatment failure: “A composite end point measuring time from randomization to discontinuation of the treatment for any reason, including disease progression, treatment toxicity, or death”
- Overall survival (OS): “Defined as time from randomization to death.”
| Q4. How Is Kaplan–meier Survival Analysis Plot Prepared?|| |
While preparing for the K-M survival analysis, each patient requires three variables:
- their serial time [Figure 1]
- their status (with respect to the event of interest, whether occurred or censored) at the end of their serial time
- If the study has more than one group, the study group to which they belong. These components may be displayed in [Table 1].
For the construction of survival time probabilities and curves, the serial times for individual patients are usually arranged from the shortest to the longest, without considering when they entered the study (i.e., the calendar time). By doing this, all patients within a particular group begin the analysis at the same point and all are surviving until something (an event) occurs to them.
| Q5. How Is Kaplan–meier Survival Plot Interpreted|| |
[Figure 2] shows a survival curve of 78 breast cancer patients with a median follow-up of 54 months. Group 1 is patients who had pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) and Group 2 includes patients with no pCR to NACT. The different survival is shown in the two separate curves. The interpretation of each component is as follows:
- Number of Survival curves: indicates the number of different groups of patients in a study
- Length of Horizontal lines along X-axis of serial time: it represents the survival duration for that interval (definition of interval). A particular interval ends when the event of interest occurs
- Vertical distances between horizontal line: illustrate the change in cumulative probability as curve advances, which means, that as more events occur, the curve keeps moving down, which decreases the probability of survival as the serial time increases
- Censoring is indicated by the + sign in each curve and is usually depicted in the curve.
| Q6. How Are Different Study Groups Compared in Kaplan–meier Survival Analysis?|| |
- Is the one of the most commonly used tests for comparison of two groups in the survival analysis
- It compares two survival curves using a test with statistical hypothesis
- It uses the null hypothesis indicating that there is no difference between the two population survival curves
- It calculates the Chi-square test at each event time, for each group and then sums up the results
- The summed-up results of each group are added to derive the ultimate Chi-square to compare full curves of each group.
- It is similar to the log rank test described above
- However, it has the ratio of hazard rates
- It quantifies the likelihood that a patient will have a hazardous event (negative event) or a hazard during a predefined interval of observation
- Expressed as rate or percentage.
| Q7. What Are Different Kaplan–meier Curves Used in Oncology?|| |
- Overall survival curves
- Disease-free survival curves
- Progression-free survival curves.
| Q8. What Are Pitfalls of Kaplan–meier Survival Analysis?|| |
- Must identify the event of interest and units of the measurement along the axes.
- Shape of the curve:
- If too many small steps → a greater number of patients participating
- If too large steps → less patients participating.
- Amount and distribution of censored subject implication
- If no censoring: interpret data with caution
- If large number of censoring.
- To question as to why the study was carried out
- If the treatment was ineffective.
- The log rank test assumes that the hazard ratio is constant over time.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958; 53:457-81.
Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B, Wang EW. A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg 2010;143:331-6.
Bewick V, Cheek L, Ball J. Statistics review 12: Survival analysis. Crit Care 2004;8:389-94.
Bates S, FojoT. Assessment of Clinical Response in Cancer DeVita, Hellman, and Rosenberg's Cancer Principles Practice of Oncology. 11th
ed. Philadelphia: Wolters Kluwer; 2019.
[Figure 1], [Figure 2]